The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Focus Areas:  The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:

·         Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways

·         Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures

·         Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions

·         Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization

 

https://cdmrp.army.mil/funding/tscrp

 

Submission Deadline Extension

 

Exploration – Hypothesis Development Award – Letter of Intent due July 9, 2019

·         Investigators at all academic levels (or equivalent), including postdoctoral fellows

·         Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.

·         Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

·         Preliminary data are not required.

• ·         Clinical trials not allowed.

·         The maximum allowable funding for the entire period of performance is $150,000 in direct costs.

·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·         Maximum period of performance is 2 year

 

Idea Development Award – Letter of Intent due July 9, 2019

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);

Or

New Investigators:  Independent investigator at or below the level of Assistant Professor (or equivalent); or Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC.

·         Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.

·         Preliminary data are expected.

·         Clinical trials not allowed.

·         New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in TSC research.

• ·         Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately

·         The maximum allowable funding for the entire period of performance is $450,000 for direct costs.

·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·         Maximum period of performance is 3 years

 

Clinical Translational Research Award – Letter of Intent due July 9, 2019

• ·         Independent investigators at or above the level of Assistant Professor (or equivalent)

·         Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.

·         Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.

·         Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 

·         Preclinical studies may be appropriate but must include a clinical component.

·         Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.

·         Projects that are exploratory and/or strictly animal research will not be considered for funding.

·         Preliminary data required.

·         The maximum allowable funding for the entire period of performance is $600,000 in direct costs.

·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·         Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Tick-Borne Disease Research Program (TBDRP)to support innovative, high-impact tick-borne disease research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 TBDRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 TBDRP must address at least one of the following specific Focus Areas in Lyme disease and other tick-borne diseases:

• Diagnosis

• o   Accurate diagnostics and biomarkers for Lyme disease and co-infections and/or other tick-borne diseases
• o   Diagnostic biomarkers for Lyme disease that distinguish between active infection and previous exposure, and/or monitor response to treatment

• Pathogenesis

• o   Pathogenic mechanisms, including immune protection, for Lyme disease, other tick-borne diseases, and/or co-infections
• o   Complex biology of Lyme borrelia in the host (beyond in vitro studies), including its survival, evasion of the host immune system, and subversion of the effectiveness of antibiotics
• o   Underlying mechanisms of persistent symptoms associated with Lyme disease

• Prevention

• o        Safe and effective human vaccines for tick-borne diseases
• o        Identification, validation, and/or improvement of tick-targeted prevention and control interventions
• o        Ecology of understudied tick-borne disease vectors and reservoirs with emphasis on how it relates to human risk.

• Treatment

• o   Antibiotic combinations and/or therapeutic options for treating acute and persistent illness
• o  

https://cdmrp.army.mil/funding/tbdrp

Investigator-Initiated Research Award – Preproposal; due May 22, 2017

• Independent investigators at or above the level of Assistant Professor (or equivalent)

• ·       To fund highly rigorous, high-impact studies that have the potential to make important contributions to Lyme disease and other tick-borne disease research, patient care, and/or quality of life.
• ·       Applications should articulate both the short- and long-term impact of the proposed research, as well as the public health burden of the disease being addressed.
• ·       Preliminary or published data to support feasibility are required.
• ·       Promotes any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies; however, clinical trials are not allowed.
• ·       Maximum funding of $650K for direct costs (plus indirect costs)

• Maximum period of performance is 3 years

Idea Award – Preproposal due May 22, 2019

• Independent investigators at or above the level of Assistant Professor (or equivalent)

• ·       To fund conceptually innovative, high-risk/potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses.
• ·       Applications should articulate the qualities that make the research innovative (not merely an incremental advance), as well as the public health burden of the disease being addressed.
• ·       Preliminary data that are relevant to the proposed research project are encouraged, but not required.
• ·       Clinical trials are not allowed.
• ·       Maximum funding of $300K for direct costs (plus indirect costs)

• Maximum period of performance is 2 years

Career Development Award – Letter of Intent due May 22, 2019

• Principal Investigator (PI): 
• Early-career research scientist or physician scientist within 10 years of completing terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded
• Mentor:  Independent investigators at or above the level of Associate Professor (or equivalent); must have a proven funding and publication record in tick-borne disease research
• The PI and Mentor do not need to be located at the same organization.
• To fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• Career Development Plan is required.  Plan should be prepared with appropriate guidance from the Mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the PI will gain experience in tick-borne disease research.  PI’s institution must demonstrate a commitment to the PI through a minimum of 75% protected time for tick-borne disease research.

• ·       Preliminary data are not; however, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.

• Clinical trials are not allowed.

• ·       Maximum funding of $250K for direct costs (plus indirect costs)

• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil/).

Point of Contact:

CDMRP Help Hesk
301-682-5507
help@eBrap.org

WASHINGTON, DC - If you are reading this sentence, Happy April Fools Day from NAVREF! But guess what? This isn't necessarily all a joke either! NAVREF is proud to truly and honestly announce that for the 2019-2020 membership renewal year, NAVREF dues will undergo an unprecedented overall reduction.

So how much of a reduction are we talking about? The new maximum dues amount will be capped at $10,000 which will immediately reduce dues for the 13 largest NPCs based on last year's renewal information. ALL other NPCs will be receiving a 10% cut clear across the board.

How long will the dues reduction be in place? As of right now NAVREF is anticipating a minimum of 3 years guaranteed reduction with the goal to keep the cut permanently. Your continued support over the past 27 years has placed NAVREF in a formidable position with healthy reserves which we are now turning into a member benefit for all of our members.

Have questions? We bet you do. Submit your questions to Hawk @ htran@navref.org

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP)to support promising, necessary research for treatment of burdensome and very prevalent auditory system injury.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The HRRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 HRRP Program Announcement and General Application Instruction for the following award mechanism are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19hrrppreann

Focused Research Award

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

Preproposal is required; application submission is by invitation only.

·      Supports promising research that has the potential to make, or lead to, significant advancement in hearing restoration.

·      Must address at least one of FY19 HRRP Focus Areas:

• Develop or validate techniques/methods to assess or diagnose auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders.  For example: diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders; diagnostic tools for use in forward or remote deployed settings; treatments for the various types of damage that result in auditory dysfunction.
• Accelerate translation of biological regeneration/repair mechanisms into therapies that restore auditory function.
• Develop reliable in vitro human models for evaluating hearing restoration therapies.  

·      It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·      Funding Level 1 requires preliminary data to support the rationale of the research idea and the investigating team’s expertise in the subject area.

·      Funding Level 2 requires preliminary data to support the feasibility of the proposed research strategy.

·      Funding Level 2 may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

Tinnitus or vestibular-related research is excluded.

Funding Level 1:

·        Maximum funding of $250,000 for direct costs (plus indirect costs)

·        The maximum period of performance is 2 years.

Funding Level 2:

·        Maximum funding of $1M for direct costs (plus indirect costs)

·        The maximum period of performance is 3 years.

Funding Level 2 with Pilot Clinical Trial Option:

·        Maximum funding of $1.25M for direct costs (plus indirect costs)

The maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP)to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The SCIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

For FY19, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY19 Focus Areas:

• Neuroprotection
• Biomarkers
• Bladder dysfunction,  bowel dysfunction and neuropathic pain
• Psychosocial issues relevant to SCI in  individuals with SCI or their caregivers
• Rehabilitation and regeneration

https://cdmrp.army.mil/pubs/press/2019/19scirppreann

Clinical Trial Award

Independent investigators at all academic levels (or equivalent)

·    Preproposal is required; application submission is by invitation only.

·    Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.

·    Applications must include at least two SCI consumer advocates as members of the research team.

·    Preclinical data required for all clinical trial applications.

·     Maximum funding of $3M for direct costs (plus indirect costs)

·      Maximum period of performance is 4 years

Investigator-Initiated Research Award

Independent investigators at all academic levels (or equivalent)

·    Preproposal is required; application submission is by invitation only.

·    Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.

·  Preliminary data required.

·  Clinical trials not allowed.

·     Maximum funding of $500,000 for direct costs (plus indirect costs)

·  Maximum period of performance is 3 years.

Translational Research Award

Independent investigators at all academic levels (or equivalent)

·      Preproposal is required; application submission is by invitation only.

·      Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.

·      Applications must include at least one SCI consumer advocate as a member of the research team.

·      Preliminary data required

The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

·     Maximum funding of $1.25M for direct costs (plus indirect costs)

·      Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19kcrppreann

Concept Award

Investigators at all academic levels

• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
• Emphasis on innovation
• Funding for clinical trials not allowed
• Preliminary data not allowed
• Blinded review
• Maximum funding of $75,000 for direct costs (plus indirect costs)
• Maximum period of performance 1 year

Idea Development Award

Established Investigators: 

Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

Early Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible

·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer

·      Preliminary data required

·      Innovation and Impact the most important review criteria

·      Funding for clinical trials not allowed

• FY19 KCRP Areas of Emphasis strongly encouraged
• Maximum funding of $400,000 in direct costs (plus indirect costs)
• Maximum period of performance 2 years

Translational Research Partnership Award

Investigators at or above the level of Assistant Professor (or equivalent)

·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications

·     Supports translational correlative studies

·      Preliminary data required

·      Funding for clinical trials not allowed

·     Maximum funding of $600,000 for direct costs (plus indirect costs)

·      Maximum period of performance 3 years

Kidney Cancer Academy Dean Award

Dean must be an independent, established kidney cancer researcher with a record of kidney cancer research funding and publications in peer-reviewed journals

·      Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership

·      Academy Dean will oversee an interactive virtual academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs

·     Maximum funding of $500,000 for direct costs (plus indirect costs)

·      Maximum period of performance 4 years

Kidney Cancer Academy Early Career Investigator Award

Within 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline

Letter attesting to eligibility required

·      Supports addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty

·      ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply

·      Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding

·      Designated Mentor not required to be at the same institution as the ECI

·      Preliminary data required

·      Clinical trials allowed

·     Maximum funding of $725,000 for direct costs (plus indirect costs)

·      Maximum period of performance 4 years

Clinical Consortia Award

Independent Investigators at or above the level of Assistant Professor (or equivalent)

·      Supports development of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer

·      Funds may not be used for research or development of clinical protocols

·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged

·      One (1) Coordinating Center and three (3) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials

·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

·      Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends

Coordinating Center:

·      Maximum funding of $3,000,000 for direct costs (plus indirect costs)

·     Maximum period of performance 3 years

Clinical Trial Sites:

·     Maximum funding of $600,000 for direct costs (plus indirect costs)

·      Maximum period of performance 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP) to support specific Defense Health Agency (DHA) J9 Research and Development Directorate program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PH/TBIRP and JPC-5/MOMRP are providing the information in this pre-announcement to allow investigators time to plan and develop applications.  The FY19 PHTBIRP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19phtbipreann

Prevention Research to Reduce Sexual Assault and/or Understand Adjustment Disorders (PSAAD)

Intramural (DoD) and extramural investigators at Assistant Professor level or above (or equivalent) are eligible to submit applications.

Applications to the FY19 PHTBIRP PSAAD Investigator Initiated Focused Research Award should address the development or adaptation of prevention efforts to reduce the occurrence of sexual assault or address approaches to better understand, screen for, and prevent Adjustment Disorders among Service members, ultimately benefiting the public at large.

·       The maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.

·       The maximum period of performance is 3 years.

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PHTBIRP or other CDMRP-administered and supported programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

 

FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:

 

• Identify innovative strategies for the screening and early detection of lung cancer.
• Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• Identify innovative strategies for prevention of the occurrence of lung cancer.
• Identify innovative strategies for the treatment of lung cancer.
• Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
• Develop or optimize predictive markers to assist with therapeutic decision-making.
• Understand mechanisms of resistance to treatment (primary and secondary).
• Understand contributors to lung cancer development other than tobacco.
• Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

 

Military Relevance:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

 

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
• Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

 

https://cdmrp.army.mil/funding/lcrp

 

 

Career Development Award – Letter of Intent due August 1, 2019

·         Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment.

·         Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.

·         Must not have received more than $300,000 in total direct costs for previously or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants.

·         Mentor:

·         At or above the level of Associate Professor (or equivalent)

·         Must have a proven publication and funding record in lung cancer research.

·         Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.

·         Clinical trials not allowed.

·         Preliminary data not required.

• ·         Relevance to Military Health strongly encouraged.

·         Maximum funding of $250,000 in direct costs (plus indirect costs).

• ·         Period of performance should not exceed 2 years.

Idea Development Award –Preproposal due May 15, 2019

• ·         Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
• ·         New Investigators:  Investigators must meet the following criteria at the application submission deadline date:

·         Have not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award

• ·         Be within 10 years of first faculty appointment (or equivalent)

• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.

• ·         Relevance Military Health strongly encouraged.

·         Maximum funding of $350,000 in direct costs (plus indirect costs).

• ·         Period of performance should not exceed 2 years.

 

Investigator-Initiated Translational Research Award – Preproposal due May 15, 2019

• ·         Independent investigators at or above the level of Assistant Professor (or equivalent)

• Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.
• Intended to fund a broad range of translational studies.
• Clinical trials not allowed.
• Preliminary data required.

• ·         Relevance to Military Health strongly encouraged.

·         Maximum funding of $400,000 in direct costs (plus indirect costs).

• ·         Period of performance should not exceed 2 years.

 

Translational Research Partnership Award – Preproposal due May 15, 2019

• ·         Investigators at or above the level of Assistant Professor (or equivalent)

• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.

• ·         One partner is strongly encouraged to be from Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center.
• ·         Clinical trials are allowed.

• Nontraditional Partnerships are encouraged.
• Preliminary data required.

• ·         Relevance to Military Health strongly encouraged.

• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $90 million (M) to the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY19 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted.

The FY19 PRCRP Topic Areas are:

·        Bladder cancer ·        Blood cancers ·        Brain cancer ·        Cancer in children, adolescents, and young adults*

Colorectal cancer Immunotherapy† Listeria vaccine for cancer Liver cancer Lymphoma Mesothelioma

Neuroblastoma Pancreatic cancer Pediatric brain tumors Rare cancersǂ Stomach cancer

*The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between 15 and 39 years of age.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^†As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

^ǂRare cancer is defined by the National Cancer Institute as a cancer that occurs in fewer than 15 out of 100,000 people each year.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY19 PRCRP Military Relevance Focus Areas are listed below:

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health and mission readiness of both deployed and non-deployed personnel, their dependents, retirees, and Veterans. The FY19 PRCRP requires all applications to respond to at least one of Military Relevance Focus Areas listed below:

• Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
• Gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public

https://cdmrp.army.mil/funding/prcrp

Career Development Award – Letter of Intent due August 21, 2019

Principal Investigator (PI): Independent investigator within 10 years of completing terminal degree (excluding time spent in medical residency, clinical training, or on family medical leave) by the time of the application submission; time spent as a postdoctoral fellow is not excluded.

Postdoctoral fellows are not eligible.

Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

The PI and the Career Guide do not need to be located at the same organization.\

• Letter of Intent is required.  An invitation to submit a full application is not required.
• Supports independent, early-career investigators to conduct impactful research, together with the guidance of an experienced cancer researcher.
• Must address at least one of the FY19 PRCRP Topic Areas.
• Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• Preliminary data are not required.
• Clinical trials are not allowed.

·      Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

Horizon Award – Letter of Intent due August 21, 2019

Principal Investigator (PI):

Predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her Mentor’s laboratory application submission deadline.

Or

Postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her Mentor’s laboratory at application submission deadline.

Mentor: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven publication and funding record in cancer research. 

PI and Mentor must be at the same organization.

• Letter of Intent is required.  An invitation to submit a full application is not required.
• Supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor).
• Must address at least one of the FY19 PRCRP Topic Areas.
• Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• Preliminary data are not required.
• Clinical trials are not allowed.

·      Maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 2 years.

Idea Award with Special Focus –Preproposal due May 22, 2019

Independent investigator with a faculty-level appointment (or equivalent).

• Preproposal is required; application submission is by invitation only.
• Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, Veterans, military beneficiaries, and the American public.
• Emphasis on innovation and military relevance/impact.
• Must address at least one of the FY19 PRCRP Topic Areas.
• Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• Inclusion of preliminary data are not required.
• Clinical trials are not allowed.

·      Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 2 years.

Impact Award – Preproposal due May 22, 2019

Independent investigators at or above the level of Assistant Professor (or equivalent).

Only one pre-application per PI is allowed.

• Preproposal is required; application submission is by invitation only.
• Supports hypothesis-driven, high impact research.
• Encourages applications that support the ideas that specifically focus on critical scientific and clinical cancer issues.
• Emphasis on impact, transformation, and continuity of research.
• Must address at least one of the FY19 PRCRP Topic Areas.
• Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• Preliminary data are required.
• Clinical Trials are allowed.

·      Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

Translational Team Science Award – Preproposal due May 22, 2019

At least two and up to three PIs must partner in one overarching correlative or translational research study in at least one of the required FY19 PRCRP Topic Areas.

The PIs must be at or above the level of Assistant Professor or equivalent.

• Preproposal is required; application submission is by invitation only.
• Emphasizes multi-PI, multidisciplinary collaborations.
• Supports hypothesis-driven translational studies that are associated with an ongoing or completed clinical trial and are focused on research for the next-phase clinical research.
• Must address at least one of the FY19 PRCRP Topic Areas.
• Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• Encourages research in interventions to improve the quality of life, cancer prevention, and metastasis.
• Preliminary data are required.
• Clinical Trials are allowed.

·      Maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The Fiscal Year 2019 (FY19) Defense Appropriation provides $30 million (M) to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support the most significant gaps in care for the leading burden of injury and for facilitating return to duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC). 

The PRORP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRORP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website by June 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

The PRORP will solicit research applications that specifically address at least one of the following FY19 Focus Areas:

• 1.     Compartment Syndrome Models: Diagnostic and/or treatment strategies developed in a large animal model that replicates compartment syndrome.  Model system should be clinically relevant and scientifically reproducible.
• 2.     Limb Stabilization and Protection: Development of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.
• 3.     Retention on Duty Strategies: Development and/or optimization of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  (Biomarker studies are excluded.)
• 4.     Skin-implant Interface: Identification of best practices to address infection at the skin-implant interface for osseointegrated prosthetic limbs.
• 5.     Translation of Early Findings: Translation of early research findings in orthopaedic surgical care topic areas (volumetric muscle loss, compartment syndrome, and soft tissue trauma) to move the research toward clinical trials and clinical practice.
• 6.     Tissue Regeneration Therapeutics: Development of advanced tissue regeneration therapeutics in nerve, muscle, and/or composite tissue for the restoration of traumatically injured extremities (excludes isolated bone tissue engineering studies).

The following FY19 PRORP award mechanisms are planned for release (note that Focus Area requirements vary by award mechanism):

https://cdmrp.army.mil/pubs/press/2019/19prorppreann

Applied Research Award

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·     Pre-application is required; full application submission is by invitation only. ·     Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities. ·     Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation. ·     Clinical trials are not allowed under this award mechanism. ·     Applications must address one the following FY19 PRORP Focus Areas: o   Compartment Syndrome Models o   Limb Stabilization and Protection

• Retention on Duty Strategies

·       Maximum funding of $750,000 for total costs (direct plus indirect costs).

·       Maximum period of performance is 3 years.

Clinical Trial Award

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·     Pre-application is required; full application submission is by invitation only. ·     Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates. ·     Funding must support a clinical trial and may not be used for preclinical research studies. ·     Collaboration with military researchers and clinicians is encouraged. ·     Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date. ·     Applications must address one the following FY19 PRORP Focus Areas: o   Limb Stabilization and Protection o   Retention on Duty Strategies o   Translation of Early Findings

Applications submitted to the Translation of Early Findings (soft tissue trauma only) Focus Area may elect a Rehabilitation Option, which provides a higher funding maximum for surgical intervention studies that propose an integrative rehabilitation component.

·       Maximum funding of $2.5M for total costs. ($3M maximum total costs if requesting the Rehabilitation Option.)

• ·      Maximum period of performance is 4 years.

Clinical Translational Research Award

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·     Pre-application is required; full application submission is by invitation only. ·     Supports high-impact and/or emerging research that may or may not be ready for a full-scale, randomized, controlled clinical trial. ·     Funding must support clinical research studies involving humans. ·     Preliminary or published data relevant to the proposed research project are required. ·     Collaboration with military researchers and clinicians is encouraged. ·     Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 12 months of the award date. ·     Applications must address one the following FY19 PRORP Focus Areas: o   Retention on Duty Strategies

• Tissue Regeneration Therapeutics

·       Maximum funding of $2M for total costs.

·       Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil